Chinese company BrainCo is developing a wearable device intended to suppress appetite through brain stimulation. The company positions this technology as a potential alternative to GLP-1-based obesity medications such as Wegovy and Zepbound.
Co-founder Nyx He predicts the device will be released in two to three years, initially in China, followed by entry into the US market. According to Bloomberg, this proposal is still in the development stage and aims to bring brain-computer interface technology to the weight loss market.
The device will utilize a brain-computer interface (BCI) to influence neural signals associated with appetite control. BrainCo intends to apply this technology to affect the brain mechanisms responsible for feelings of hunger.
During an interview at Bloomberg Tech London, she described the project as an 'electronic version of GLP-1-based obesity drugs.' However, she emphasized that this is the company's commercial proposition, not proven therapeutic equivalence.
BrainCo's approach differs from the method used by existing drugs. While Wegovy and Zepbound mimic metabolic hormones that regulate appetite, BrainCo plans to act through brain stimulation, without relying on medication.
Currently, the company has not disclosed results confirming the device's effectiveness in reducing appetite or weight loss. Sufficient details regarding the stimulation mechanisms or testing results for this technology have also not been revealed.
The company is considering various commercialization models, including versions intended for medical use and others directly aimed at consumers.
BrainCo, based in Hangzhou, China, is already active in neurotherapy, prosthetics, and robotics. Its products include non-invasive brain-computer interface headphones sold for treating conditions such as autism, attention deficit hyperactivity disorder (ADHD), and insomnia.
These devices collect and decode neural signals and can stimulate them in some cases. Furthermore, the company is developing hand prosthetics that allow amputees and people with disabilities to control artificial fingers using brain signals.
The company's main areas of activity include:
Despite the focus on non-invasive technologies, He stated that BrainCo may explore approaches requiring brain implants in the future.
BrainCo's operations in the US occur amid increased geopolitical scrutiny of brain-computer interface technologies. Among the discussed proposals are American restrictions on investment in Chinese companies in this sector.
Nevertheless, He stated that the company continues to observe high demand for its prosthetics and robotic arms in the American market and expects accelerated growth.



